Document:

Exhibit
10.2

 

 

CONFIDENTIAL

 

April
9, 2021

 

VIA
ELECTRONIC DELIVERY

 

Mr.
Robert Mattacchione

Chairman
& Chief Executive Officer

Novo
Integrated Sciences, Inc.

11120
NE 2nd Street, Suite 100

Bellevue,
WA 98004

 

Dear
Mr. Mattacchione:

 

This
letter (the “Agreement”) constitutes the agreement between Maxim Group LLC (“Maxim” or the
“Placement Agent”) and Novo Integrated Sciences, Inc., a Nevada corporation (the “Company”),
that Maxim shall serve as the placement agent for the Company, on a “commercially reasonable best efforts” basis,
in connection with the proposed placement (the “Placement”) of common stock (the “Shares”)
of the Company, par value $0.001 per share (“Common Stock”) and warrants to purchase shares of Common Stock
(“Warrants” and collectively with the Shares, the “Securities”). The terms of the Placement
and the Securities shall be mutually agreed upon by the Company and the purchasers (each, a “Purchaser” and
collectively, the “Purchasers”) and nothing herein grants Maxim the power or authority to bind the Company
or any Purchaser or creates an obligation for the Company to issue any Securities or complete the Placement. This Agreement and
the documents executed and delivered by the Company and the Purchasers in connection with the Placement, including but not limited
to the Purchase Agreement (as defined below) and the Warrants shall be collectively referred to herein as the “Transaction
Documents.” The date of the closing of the Placement (the “Closing”) shall be referred to herein
as the “Closing Date.” The Company expressly acknowledges and agrees that Maxim’s obligations hereunder
are on a commercially reasonable best efforts basis only and that the execution of this Agreement does not constitute a commitment
by Maxim to purchase the Securities and does not ensure the successful placement of the Securities or any portion thereof or the
success of Maxim with respect to securing any other financing on behalf of the Company. The Placement Agent may retain other brokers
or dealers to act as sub-agents or selected-dealers on its behalf in connection with the Placement. The sale of the Securities
to any Purchaser will be evidenced by a share purchase agreement (the “Purchase Agreement”) between the Company
and such Purchaser in a form reasonably acceptable to the Company and Maxim. Capitalized terms that are not otherwise defined
herein have the meanings given to such terms in the Purchase Agreement. Prior to the signing of any Purchase Agreement, officers
of the Company will be available to answer inquiries from prospective Purchasers.

 

Notwithstanding
anything herein to the contrary, in the event that the Placement Agent determines that any of the terms provided for hereunder
shall not comply with a FINRA rule, including but not limited to FINRA Rule 5110, then the Company shall agree to amend this Agreement
in writing upon the request of the Placement Agent to comply with any such rules; provided that any such amendments shall not
provide for terms that are less favorable to the Company.

 

SECTION
1. Compensation and Other Fees.

 

As
compensation for the services provided by the Placement Agent hereunder, the Company agrees to pay to the Placement Agent as follows:

 

(A)
A cash fee (the “Cash Fee”) equal to an aggregate of seven percent (7%) of the aggregate gross proceeds raised
in the Placement. The Cash Fee shall be paid at the Closing.

 

    	1

    	 

    

 

(B)
Subject to compliance with FINRA Rule 5110(f)(2)(D), the Company agrees to reimburse Maxim for all reasonable travel and other
out-of-pocket expenses, including the fees of legal counsel, in an amount not to exceed $100,000 (the “Expenses”).
An advance of $25,000 has been received by the Placement Agent, which amount will be applied towards the Expenses at Closing.

 

The
Placement Agent reserves the right to reduce any item of compensation or adjust the terms thereof as specified herein in the event
that a determination shall be made by FINRA to the effect that the Placement Agent’s aggregate compensation is in excess
of FINRA Rules or that the terms thereof require adjustment.

 

SECTION
2. REPRESENTATIONS AND WARRANTIES OF THE PLACEMENT AGENT. Maxim represents and warrants that it (i) is a member in good
standing of FINRA, (ii) is registered as a broker/dealer under the Securities Exchange of 1934, as amended (the “Exchange
Act”), (iii) is licensed as a broker/dealer under the laws of the States applicable to the offers and sales of the Securities
by Maxim, (iv) is and will be a body corporate validly existing under the laws of its place of incorporation, and (v) has full
power and authority to enter into and perform its obligations under this Agreement. Maxim will immediately notify the Company
in writing of any change in its status as such. Maxim covenants that it will use its reasonable best efforts to conduct the Placement
hereunder in compliance with the provisions of this Agreement and the requirements of applicable law.

 

SECTION
3. REPRESENTATIONS, WARRANTIES AND COVENANTS OF THE COMPANY.

 

(a)
Representations of the Company. Each of the representations and warranties (together with any related disclosure schedules
thereto) and covenants made by the Company to the Purchasers in the Purchase Agreement in connection with the Placement is hereby
incorporated herein by reference into this Agreement (as though fully restated herein) and is, as of the date of this Agreement
and as of the Closing Date, hereby made to, and in favor of, the Placement Agent. In addition to the foregoing, the Company represents
and warrants that:

 

1.
The Company has prepared and filed with the Securities and Exchange Commission (the “Commission”) a registration
statement on Form S-3 (Registration No. 333-254278), and amendments thereto, and related preliminary prospectuses, for the registration
under the Securities Act of 1933, as amended (the “Securities Act”), of the Shares, which registration statement,
as so amended (including post-effective amendments, if any) became effective on March 22, 2021, for the registration under the
Securities Act of the Shares. At the time of such filing, the Company met the requirements for use of Form S-3 under the Securities
Act, including the transaction requirements set forth in General Instruction I.B.6 of that form. Such registration statement meets
the requirements set forth in Rule 415(a)(1)(x) under the Securities Act and complies with said Rule. The Company will file with
the Commission pursuant to Rule 424(b) under the Securities Act, and the rules and regulations (the “Rules and Regulations”)
of the Commission promulgated thereunder, a supplement to the form of prospectus included in such registration statement relating
to the placement of the Shares and the plan of distribution thereof and has advised the Placement Agent of all further information
(financial and other) with respect to the Company required to be set forth therein. Such registration statement, including the
exhibits thereto, as amended at the date of this Agreement, is hereinafter called the “Registration Statement”;
such prospectus in the form in which it appears in the Registration Statement is hereinafter called the “Base Prospectus”;
and the supplemented form of prospectus, in the form in which it will be filed with the Commission pursuant to Rule 424(b)
(including the Base Prospectus as so supplemented) is hereinafter called the “Prospectus Supplement.” Any reference
in this Agreement to the Registration Statement, the Base Prospectus or the Prospectus Supplement shall be deemed to refer to
and include the documents incorporated by reference therein (the “Incorporated Documents”) pursuant to Item
12 of Form S-3 which were filed under the Exchange Act on or before the date of this Agreement, or the issue date of the Base
Prospectus or the Prospectus Supplement, as the case may be; and any reference in this Agreement to the terms “amend,”
“amendment” or “supplement” with respect to the Registration Statement, the Base Prospectus or the Prospectus
Supplement shall be deemed to refer to and include the filing of any document under the Exchange Act after the date of this Agreement,
or the issue date of the Base Prospectus or the Prospectus Supplement, as the case may be, deemed to be incorporated therein by
reference. All references in this Agreement to financial statements and schedules and other information which is “contained,”
“included,” “described,” “referenced,” “set forth” or “stated” in
the Registration Statement, the Base Prospectus or the Prospectus Supplement (and all other references of like import) shall be
deemed to mean and include all such financial statements and schedules and other information which is or is deemed to be incorporated
by reference in the Registration Statement, the Base Prospectus or the Prospectus Supplement, as the case may be. No stop order
suspending the effectiveness of the Registration Statement or the use of the Base Prospectus or the Prospectus Supplement has
been issued, and no proceeding for any such purpose is pending or has been initiated or, to the Company’s knowledge, is
threatened by the Commission. For purposes of this Agreement, “free writing prospectus” has the meaning set
forth in Rule 405 under the Securities Act and the “Time of Sale Prospectus” means the Base Prospectus, any
preliminary prospectus supplement, if any, together with the free writing prospectuses, if any, used in connection with the Placement,
including any documents incorporated by reference therein.

 

    	2

    	 

    

 

2.
The Registration Statement (and any further documents to be filed with the Commission) contains all exhibits and schedules as
required by the Securities Act. Each of the Registration Statement and any post-effective amendment thereto, at the time it became
effective, complied in all material respects with the Securities Act and the applicable Rules and Regulations and did not and,
as amended or supplemented, if applicable, will not, contain any untrue statement of a material fact or omit to state a material
fact required to be stated therein or necessary to make the statements therein not misleading. The Base Prospectus, the Time of
Sale Prospectus, if any, and the Prospectus Supplement, each as of its respective date, comply in all material respects with the
Securities Act and the applicable Rules and Regulations. Each of the Base Prospectus, the Time of Sale Prospectus, if any, and
the Prospectus Supplement, as amended or supplemented, did not and will not contain as of the date thereof any untrue statement
of a material fact or omit to state a material fact necessary in order to make the statements therein, in light of the circumstances
under which they were made, not misleading. The Incorporated Documents, when they were filed with the Commission, conformed in
all material respects to the requirements of the Exchange Act and the applicable Rules and Regulations, and none of such documents,
when they were filed with the Commission, contained any untrue statement of a material fact or omitted to state a material fact
necessary to make the statements therein (with respect to Incorporated Documents incorporated by reference in the Base Prospectus
or Prospectus Supplement), in light of the circumstances under which they were made not misleading; and any further documents
so filed and incorporated by reference in the Base Prospectus, the Time of Sale Prospectus, if any, or Prospectus Supplement,
when such documents are filed with the Commission, will conform in all material respects to the requirements of the Exchange Act
and the applicable rules and regulations thereunder, as applicable, and will not contain any untrue statement of a material fact
or omit to state a material fact necessary to make the statements therein, in light of the circumstances under which they were
made, not misleading. No post-effective amendment to the Registration Statement reflecting any facts or events arising after the
date thereof which represent, individually or in the aggregate, a fundamental change in the information set forth therein is required
to be filed with the Commission. There are no documents required to be filed with the Commission in connection with the transaction
contemplated hereby that (x) have not been filed as required pursuant to the Securities Act or (y) will not be filed within the
requisite time period. There are no contracts or other documents required to be described in the Base Prospectus, the Time of
Sale Prospectus, if any, or Prospectus Supplement, or to be filed as exhibits or schedules to the Registration Statement, which
(x) have not been described or filed as required or (y) will not be filed within the requisite time period. The Warrants shall
be offered and sold in a simultaneous private placement transaction pursuant to an exemption from the registration requirements
of Section 5 of the Securities Act of 1933, as amended, contained in Section 4(a)(2) thereof and/or Regulation D thereunder.

 

3.
The Company has delivered, or will as promptly as practicable deliver, to the Placement Agent complete conformed copies of the
Registration Statement and of each consent and certificate of experts, as applicable, filed as a part thereof, and conformed copies
of the Registration Statement (without exhibits), the Base Prospectus, the Time of Sale Prospectus, if any, and the Prospectus
Supplement, as amended or supplemented, in such quantities and at such places as the Placement Agent reasonably requests. Maxim
acknowledges that all such materials as exist on the date of this letter, and are available on EDGAR in satisfaction of the foregoing
sentence. Neither the Company nor any of its directors and officers has distributed and none of them will distribute, prior to
the Closing Date, any offering material in connection with the offering and sale of the Securities other than the Base Prospectus,
the Time of Sale Prospectus, if any, the Prospectus Supplement, the Registration Statement, copies of the documents incorporated
by reference therein and any other materials permitted by the Securities Act.

 

4.
As of the date of this Agreement and provided the Shares do not exceed 20.0% of the outstanding shares on the Closing Date, except
for the filings with the Nasdaq or other US applicable national exchange for the listing of the Shares for trading thereon in
the time and manner required thereby, the issuance and listing on the Nasdaq or other US applicable national exchange of the Shares
requires no further approvals, including but not limited to, the approval of shareholders.

 

    	3

    	 

    

 

5.
The issuance by the Company of the Shares has been registered under the Securities Act. The Shares will be issued pursuant to
the Registration Statement and will be freely transferable and freely tradable by each of the Investors without restriction, unless
otherwise restricted by applicable law or regulation. The Company is eligible to use Form S-3 under the Securities Act and it
meets the transaction requirements with respect to the aggregate market value of the Shares being sold pursuant to the Placement
and during the twelve (12) months prior to this offering, as set forth in General Instruction I.B.6 of Form S-3.

 

(b)
FINRA Affiliations. There are no affiliations with any FINRA member firm among the Company’s officers, directors
or, to the knowledge of the Company, any five percent (5.0%) or greater stockholder of the Company, except as set forth in the
Base Prospectus.

 

(c)
Lock-Up. The Company hereby agrees, for a period of one hundred eighty (180) days after the Closing (the “Lock-Up
Term”), that the Company shall neither (i) offer, issue, sell, contract to sell, encumber, grant any option for the
sale of or otherwise dispose of any securities of the Company without Maxim’s prior written consent, including the issuance
of shares of Common Stock upon the exercise of currently outstanding options approved by Maxim or (ii) file or caused to be filed
any registration statement with the Commission relating to the offering of any shares of capital stock of the Company or any securities
convertible into or exercisable or exchangeable for shares of capital stock of the Company other than a resale registration statement
in respect of shares issued prior to the date of the proposed offering contemplated.

 

Notwithstanding
anything herein to the contrary, the Company may issue shares of its capital stock or any securities convertible into or exercisable
or exchangeable for shares of its capital stock during the Lock-Up Term (i) so long as the capital stock or securities exercisable
or exchangeable for shares of its capital stock are restricted during the Lock-Up Term in accordance with Rule 144 or other contractual
arrangement, (ii) in connection with the conversion of the Company’s outstanding securities into Common Stock in connection
with the Closing; and (iii) transfers of Common Stock pursuant to a bona fide third-party tender offer, merger, consolidation
or other similar transaction that is approved by the Company’s board of directors.

 

SECTION
4. INDEMNIFICATION. The Company agrees to the indemnification and other agreements set forth in the Indemnification
Provisions (the “Indemnification”) attached hereto as Addendum A, the provisions of which are incorporated
herein by reference and shall survive the termination or expiration of this Agreement.

 

SECTION
5. ENGAGEMENT TERM. The Placement Agent’s engagement hereunder shall become effective on the date hereof and shall
continue until the later of (i) the final closing date of the Placement, (ii) September 16, 2021 (such date, the “Termination
Date”). Notwithstanding anything to the contrary contained herein, the provisions concerning confidentiality, indemnification,
contribution and the Company’s obligations to pay fees and reimburse expenses contained herein and the Company’s obligations
contained in the Indemnification Provisions will survive any expiration or termination of this Agreement, irrespective of whether
a closing occurs. All such fees and reimbursements due shall be paid to the Placement Agent on or before the Termination Date
(in the event such fees and reimbursements are earned or owed as of the Termination Date) or upon the closing of the Placement
or any applicable portion thereof (in the event such fees are due pursuant to the terms of Section 1 hereof). Maxim agrees not
to use any confidential information concerning the Company provided to them by the Company for any purposes other than those contemplated
under this Agreement.

 

SECTION
6. [Reserved.]

 

SECTION
7. PLACEMENT AGENT INFORMATION. The Company agrees that any information or advice rendered by the Placement Agent in
connection with this engagement is for the confidential use of the Company only in their evaluation of the Placement and, except
as otherwise required by law, the Company will not disclose or otherwise refer to the advice or information in any manner without
such Placement Agent’s prior written consent.

 

SECTION
8. NO FIDUCIARY RELATIONSHIP. This Agreement does not create, and shall not be construed as creating rights enforceable
by any person or entity not a party hereto, except those entitled hereto by virtue of the Indemnification Provisions hereof. The
Company acknowledges and agrees that Maxim is and shall not be construed to be a fiduciary of the Company and Maxim shall have
no duties or liabilities to the equity holders or the creditors of the Company or any other person by virtue of this Agreement
or the retention of the Placement Agent hereunder, all of which are hereby expressly waived.

 

    	4

    	 

    

 

SECTION
9. CLOSING. The obligations of the Placement Agent and the closing of the sale of the Securities hereunder are subject
to the accuracy, when made and on the Closing Date, of the representations and warranties on the part of the Company and its Subsidiaries
contained herein and in the Purchase Agreement, to the accuracy of the statements of the Company and its Subsidiaries made in
any certificates pursuant to the provisions hereof, to the performance by the Company and its Subsidiaries of their obligations
hereunder, and to each of the following additional terms and conditions:

 

(A)
No stop order suspending the effectiveness of the Registration Statement shall have been issued and no proceedings for that purpose
shall have been initiated or threatened by the Commission, and any request for additional information on the part of the Commission
(to be included in the Registration Statement, the Base Prospectus or the Prospectus Supplement or otherwise) shall have been
complied with to the reasonable satisfaction of each Placement Agent. Any filings required to be made by the Company in shall
have been timely filed with the Commission. Neither the Company nor any of its affiliates shall have, either prior to the initial
filing or the effective date of the Registration Statement, made any offer or sale of any securities which are required to be
“integrated” pursuant to the Securities Act or the regulations thereunder with the offer and sale of the Securities
pursuant to the Registration Statement.

 

(B)
The Placement Agent shall not have discovered and disclosed to the Company on or prior to the Closing Date that the Registration
Statement, the Base Prospectus or the Prospectus Supplement or any amendment or supplement thereto contains any untrue statement
of a fact which, in the opinion of counsel for the Placement Agent, is material or omits to state any fact which, in the opinion
of such counsel, is material and is required to be stated therein or is necessary to make the statements therein not misleading.

 

(C)
All corporate proceedings and other legal matters incident to the authorization, form, execution, delivery and validity of each
of this Agreement, the Securities, the Registration Statement, the Base Prospectus and the Prospectus Supplement and all other
legal matters relating to this Agreement and the transactions contemplated hereby shall be reasonably satisfactory in all material
respects to counsel for the Placement Agent, and the Company shall have furnished to such counsel all documents and information
that they may reasonably request to enable them to pass upon such matters.

 

(D)
The Placement Agent shall have received from outside counsel to the Company such counsel’s written opinion, addressed to
the Placement Agent and the Purchasers dated as of the Closing Date, in form and substance reasonably satisfactory to the Placement
Agent, substantially identical to that provided to the Purchasers.

 

(E)
Neither the Company nor any of its Subsidiaries (i) shall have sustained since the date of the latest audited financial statements
included or incorporated by reference in the Base Prospectus, any loss or interference with its business from fire, explosion,
flood, terrorist act or other calamity, whether or not covered by insurance, or from any labor dispute or court or governmental
action, order or decree, otherwise than as set forth in or contemplated by the Base Prospectus and (ii) since such date there
shall not have been any change in the capital stock or long-term debt of the Company or any of its Subsidiaries or any change,
or any development involving a prospective change, in or affecting the business, general affairs, management, financial position,
stockholders’ equity, results of operations or prospects of the Company and its Subsidiaries, otherwise than as set forth
in or contemplated by the Base Prospectus, the effect of which, in any such case described in clause (i) or (ii), is, in the judgment
of the Placement Agent, so material and adverse as to make it impracticable or inadvisable to proceed with the sale or delivery
of the Securities on the terms and in the manner contemplated by the Base Prospectus, the Time of Sale Prospectus, if any, and
the Prospectus Supplement.

 

(F)
The Common Stock is registered under the Exchange Act and, as of the Closing Date, the Shares shall be listed and admitted and
authorized for trading on the Nasdaq or other applicable US national exchange and satisfactory evidence of such action shall have
been provided to the Placement Agent. The Company shall have taken no action designed to, or likely to have the effect of terminating
the registration of the Common Stock under the Exchange Act or delisting or suspending from trading the Common Stock from the
Nasdaq or other applicable US national exchange, nor has the Company received any information suggesting that the Commission or
the Nasdaq or other US applicable national exchange is contemplating terminating such registration or listing.

 

    	5

    	 

    

 

(G)
No action shall have been taken and no statute, rule, regulation or order shall have been enacted, adopted or issued by any governmental
agency or body which would, as of the Closing Date, prevent the issuance or sale of the Securities or materially and adversely
affect or potentially and adversely affect the business or operations of the Company; and no injunction, restraining order or
order of any other nature by any federal or state court of competent jurisdiction shall have been issued as of the Closing Date
which would prevent the issuance or sale of the Securities or materially and adversely affect or potentially and adversely affect
the business or operations of the Company.

 

(H)
The Company shall have prepared and filed with the Commission a Current Report on Form 8-K with respect to the Placement, including
as an exhibit thereto this Agreement.

 

(I)
The Company shall have entered into Purchase Agreements with each of the Purchasers and such agreements shall be in full force
and effect and shall contain representations and warranties of the Company as agreed between the Company and the Purchasers.

 

(J)
FINRA shall have raised no objection to the fairness and reasonableness of the terms and arrangements of this Agreement. In addition,
the Company shall, if requested by the Placement Agent, make or authorize Placement Agent’s counsel to make on the Company’s
behalf, any filing with the FINRA Corporate Financing Department pursuant to FINRA Rule 5110 with respect to the Placement and
pay all filing fees required in connection therewith.

 

(K)
On the date of this Agreement and on the Closing Date, the Placement Agent shall have received a “comfort” letter
from the Company’s independent auditor as of each such date, addressed to the Placement Agent and in form and substance
satisfactory in all respects to the Placement Agent and Placement Agent’s counsel.

 

(L)
The Placement Agent shall have received from the Company’s management, directors and officers of 5.0% or more of the outstanding
Securities as of the effective date of the Registration Statement (and all holders of securities exercisable for or convertible
into Securities) “lock-up” agreements in customary form in favor of Maxim pursuant to which such persons and entities
shall agree during the Lock-Up Term, subject to certain exceptions set forth therein, that they shall neither offer, issue, sell,
contract to sell, encumber, grant any option for the sale of or otherwise dispose of any securities of the Company without Maxim’s
prior written consent.

 

(M)
Prior to the Closing Date, the Company shall have furnished to the Placement Agent such further information, certificates and
documents as the Placement Agent may reasonably request.

 

If
any of the conditions specified in this Section 8 shall not have been fulfilled when and as required by this Agreement, or if
any of the certificates, opinions, written statements or letters furnished to the Placement Agent or to Placement Agent’s
counsel pursuant to this Section 8 shall not be reasonably satisfactory in form and substance to the Placement Agent and to Placement
Agent’s counsel, all obligations of the Placement Agent hereunder other than those that expressly survive the termination
or expiration of this Agreement, may be cancelled by the Placement Agent at, or at any time prior to, the consummation of the
Closing. Notice of such cancellation shall be given to the Company in writing or orally. Any such oral notice shall be confirmed
promptly thereafter in writing.

 

SECTION
10. GOVERNING LAW. This Agreement will be governed by, and construed in accordance with, the laws of the State of New
York applicable to agreements made and to be performed entirely in such State. This Agreement may not be assigned by either party
without the prior written consent of the other party. This Agreement shall be binding upon and inure to the benefit of the parties
hereto, and their respective successors and permitted assigns. Any right to trial by jury with respect to any dispute arising
under this Agreement or any transaction or conduct in connection herewith is waived. Any dispute arising under this Agreement
may be brought into the courts of the State of New York or into the Federal Court located in New York, New York and, by execution
and delivery of this Agreement, the Company hereby accepts for itself and in respect of its property, generally and unconditionally,
the jurisdiction of aforesaid courts. Each party hereto hereby irrevocably waives personal service of process and consents to
process being served in any such suit, action or proceeding by delivering a copy thereof via overnight delivery (with evidence
of delivery) to such party at the address in effect for notices to it under this Agreement and agrees that such service shall
constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any
way any right to serve process in any manner permitted by law. If either party shall commence an action or proceeding to enforce
any provisions of a Transaction Document, then the prevailing party in such action or proceeding shall be reimbursed by the other
party for its attorney’s fees and other costs and expenses incurred with the investigation, preparation and prosecution
of such action or proceeding.

 

    	6

    	 

    

 

SECTION
11. ENTIRE AGREEMENT/MISC. This Agreement (including the attached Indemnification Provisions) embodies the entire agreement
and understanding between the parties hereto and supersedes all prior agreements and understandings relating to the subject matter
hereof; provided that, the parties hereto agree and acknowledge that the provisions of that certain letter of engagement by and
between the Parties for advisory services, dated as of July 31, 2020, as amended to date, shall continue on in full force and
effect which shall survive the Closing of the Placement and apply to subsequent offerings by the Company in accordance with its
terms. If any provision of this Agreement is determined to be invalid or unenforceable in any respect, such determination will
not affect such provision in any other respect or any other provision of this Agreement, which will remain in full force and effect.
This Agreement may not be amended or otherwise modified or waived except by an instrument in writing signed by both the Placement
Agent and the Company. The representations, warranties, agreements and covenants contained herein shall survive the closing of
the Placement and delivery and/or exercise of the Securities, as applicable. This Agreement may be executed in two or more counterparts,
all of which when taken together shall be considered one and the same agreement and shall become effective when counterparts have
been signed by each party and delivered to the other party, it being understood that both parties need not sign the same counterpart.
In the event that any signature is delivered by facsimile transmission or a “.pdf” format file, such signature shall
create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force
and effect as if such facsimile signature page were an original thereof.

 

SECTION
12. CONTINGENT REQUIREMENTS. The Placement shall be conditioned upon, among other things, the following:

 

(i)
Satisfactory completion by the Placement Agent of its due diligence investigation and analysis of: (a) the Company’s arrangements
with its officers, directors, employees, affiliates, customers and suppliers, (b) the audited historical financial statements
of the Company as required by the SEC (including any relevant stub periods), and (c) the Company’s projected financial results
of the fiscal years ending August 31, 2021 through 2022;

 

(ii)
The Company retaining a firm nationally recognized in the U.S. of independent PCAOB registered public accountants acceptable to
the Placement Agent, which will have responsibility for the preparation of the financial statements and the financial exhibits,
if any, to be included in the Transaction Documents, and will continue to engage accountants of comparable quality (as may be
determined by the Company’s Board of Directors or audit committee) for a period of at least three (3) years after the initial
Closing Date;

 

(iv)
From and after its listing, the Company using its best efforts to maintain its listing on Nasdaq or other applicable US national
exchange for a period of at least three years following the Closing;

 

(vi)
The Company retaining a transfer agent for the Company’s Common Stock reasonably acceptable to Maxim and continuing to retain
such transfer agent for a period of two (2) years after the Closing; and

 

(vii)
The Company engaging a financial public relations firm reasonably acceptable to Maxim, which firm shall be experienced in assisting
issuers in public offerings of securities and in their relations with their security holders, and continuing to retain such firm
for a period of two years after the Closing; and

 

(viii)
The Company obtaining, and from and after the Closing maintaining, directors and officers insurance coverage from a recognized,
financially sound and reputable institution in an amount that is prudent and customary for similarly situated companies in the
business in which it is engaged.

 

SECTION
13  NOTICES. Any and all notices or other communications or deliveries required or permitted to be provided hereunder
shall be in writing and shall be deemed given and effective on the earliest of (a) the date of transmission, if such notice or
communication is delivered via facsimile at the facsimile number specified on the signature pages attached hereto prior to 6:30
p.m. (New York City time) on a business day, (b) the next business day after the date of transmission, if such notice or communication
is delivered via facsimile at the facsimile number on the signature pages attached hereto on a day that is not a business day
or later than 6:30 p.m. (New York City time) on any business day, (c) the business day following the date of mailing, if sent
by U.S. nationally recognized overnight courier service, or (d) upon actual receipt by the party to whom such notice is required
to be given. The address for such notices and communications shall be as set forth on the signature pages hereto.

 

[REMAINDER
OF PAGE INTENTIONALLY LEFT BLANK]

 

[SIGNATURE
PAGE AND ADDENDUM A FOLLOWS]

 

    	7

    	 

    

 

We
look forward to working with the Company. Please confirm that the foregoing correctly sets forth our agreement by signing and
returning the enclosed copy of this Agreement.

 

	 	Very
    truly yours,
	 	 
	 	MAXIM
    GROUP LLC
	 	 
	 	By:
    	 /s/
    Clifford A. Teller 
	 	Name:	 Clifford
    A. Teller 
	 	Title:	 Executive
    Managing Director & Head of Investment Banking 
	 	 
	 	Address
    for notice:
	 	405
    Lexington Avenue
	 	2nd
    Floor
	 	New
    York, NY 10174

 

Accepted
and Agreed to as of

the
date first written above:

 

	Novo
Integrated Sciences, Inc. 
	 
	 	 
	By:	/s/
    Robert Mattacchione	 
	Mr.
    Robert Mattacchione	 
	Chairman
    & Chief Executive Officer	 

 

Address
for notice:

Novo
Integrated Sciences, Inc.

11120
NE 2nd Street, Suite 100

Bellevue,
WA 98004

 

[SIGNATURE
PAGE TO THE AGREEMENT]

[ADDENDUM
A FOLLOWS]

 

    	 

    	 

    

 

ADDENDUM
A

 

INDEMNIFICATION
PROVISIONS

 

In
connection with the engagement of Maxim by the Company pursuant to a placement agreement dated herein on page 1 of this Agreement,
between the Company and Maxim as it may be amended from time to time in writing (the “Agreement”), the Company
hereby agrees as follows:

 

1.
To the extent permitted by law, the Company will indemnify Maxim and each of its affiliates, stockholders, directors, officers,
employees and controlling persons (within the meaning of Section 15 of the Securities Act of 1933, as amended, or Section 20 of
the Securities Exchange Act of 1934) against all losses, claims, damages, expenses and liabilities, as the same are incurred (including
the reasonable fees and expenses of counsel), relating to or arising out of its activities hereunder or pursuant to the Agreement,
except, with regard to the Placement Agent, to the extent that any losses, claims, damages, expenses or liabilities (or actions
in respect thereof) are found in a final judgment (not subject to appeal) by a court of law to have resulted primarily and directly
from such Placement Agent’s willful misconduct or gross negligence in performing the services de-scribed herein, as the
case may be.

 

2.
Promptly after receipt by the Placement Agent of notice of any claim or the commencement of any action or proceeding with respect
to which such Placement Agent is entitled to indemnity hereunder, such Placement Agent will notify the Company in writing of such
claim or of the commencement of such action or proceeding, and the Company will assume the defense of such action or proceeding
and will employ counsel reasonably satisfactory to such Placement Agent and will pay the fees and expenses of such counsel. Notwithstanding
the preceding sentence, such Placement Agent will be entitled to employ counsel separate from counsel for the Company and from
any other party in such action if counsel for such Placement Agent reasonably deter-mines that it would be inappropriate under
the applicable rules of professional responsibility for the same counsel to represent both the Company and such Placement Agent.
In such event, the reasonable fees and disbursements of no more than one such separate counsel will be paid by the Company. The
Company will have the exclusive right to settle the claim or proceeding provided that the Company will not settle any such claim,
action or proceeding without the prior written consent of the Placement Agent, which will not be unreasonably withheld.

 

3.
The Company agrees to notify the Placement Agent promptly of the assertion against it or any other person of any claim or the
commencement of any action or proceeding relating to a transaction contemplated by the Agreement.

 

4.
If for any reason the foregoing indemnity is unavailable to Maxim or insufficient to hold Maxim harmless, then the Company shall
contribute to the amount paid or payable by Maxim as a result of such losses, claims, damages or liabilities in such proportion
as is appropriate to reflect not only the relative benefits received by the Company on the one hand and Maxim on the other, but
also the relative fault of the Company on the one hand and Maxim on the other, separately and not jointly, that resulted in such
losses, claims, damages or liabilities, as well as any relevant equitable considerations. The amounts paid or payable by a party
in respect of losses, claims, damages and liabilities referred to above shall be deemed to include any legal or other fees and
expenses incurred in defending any litigation, proceeding or other action or claim. Notwithstanding the provisions hereof, the
Placement Agent’s share of the liability hereunder shall not be in excess of the amount of fees actually received, or to
be received, by such Placement Agent under the Agreement (excluding any amounts received as reimbursement of expenses incurred
by Maxim).

 

5.
These Indemnification Provisions shall remain in full force and effect whether or not the transaction contemplated by the Agreement
is completed and shall survive the termination of the Agreement and shall be in addition to any liability that the Company might
otherwise have to any indemnified party under the Agreement or otherwise.

 

[FINAL
PAGE TO ADDENDUM A OF THE AGREEMENT]LOAN December 14, 2020

   
 LOAN
 AGREEMENT
 December 14, 2020
  
 Richard N. Jeffs (the “Lender”) of 11750 Fairtide Road, Ladysmith, BC V9G 1K5, advanced CDN$25,000 (the “Principal Sum”) to Cell MedX (Canada) Corp. (the “Borrower”) of 820 1130 Pender Street West. Vancouver, BC V6E 4A4. The Lender advanced the funds on December 14, 2020.
  
 The Borrower agrees to repay the Principal Sum on demand, together with interest calculated and compounded monthly at the rate of 6% per year (the “Interest”) calculated from December 14, 2020 (the “Effective Date”). The Borrower is liable for repayment of the Principal Sum, accrued Interest, and any additional costs that the Lender incurs in trying to collect the amount owed to him under the terms of this Loan Agreement.
  
 The Borrower will evidence the debt and its repayment of the Principal Sum and the Interest with a promissory note in the attached form.
  
 	 LENDER
	 BORROWER

	 Richard N. Jeffs
	 Cell MedX (Canada) Corp.

	  
	  

	 Per:
	 Per:

	  
	  

	  
	  

	 /s/ Richard N. Jeffs
	 /s/  Yanika Silina

	 Richard N. Jeffs
	 Yanika Silina, Director

  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 
 
  
  
 PROMISSORY NOTE
  
 	 Principal Amount: CDN$25,000
	 December 14, 2020

  
  
 FOR VALUE RECEIVED Cell MedX (Canada) Corp., (the “Borrower”) promises to pay on demand to the order of Richard N. Jeffs (the “Lender”) the sum of $25,000 lawful money of Canada (the “Principal Sum”) together with the Interest accrued on the Principal Sum calculated from December 14, 2020 (“Effective Date”) both before and after maturity, default and judgment at the Interest Rate as defined below.
  
 For the purposes of this promissory note, Interest Rate means 6 per cent per year. Interest at the Interest Rate must be calculated and compounded monthly not in advance from and including the Effective Date (for an effective rate of 6.2% per annum calculated monthly), and is payable together with the Principal Sum when the Principal Sum is repaid.
  
 The Borrower may repay the Principal Sum, and the Interest in whole or in part at any time.
  
 The Borrower waives presentment, protest, notice of protest and notice of dishonour of this promissory note.
  
  
 BORROWER
 Cell MedX (Canada) Corp.
  
 Per:
  
  
 /s/ Yanika Silina
 Yanika Silina, Director

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00326-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00326-of-00352.parquet"}]]